Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 2/20 | 0.57 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5057415 | 0.89 | ALDH1A1 (0.46) | CA1CA2MAPTCES2CES1 | |
| SCHEMBL22423019 | 0.89 | CA1 (0.60) | CA1CA2MAPTCES2CES1 | |
| SCHEMBL9301384 | 0.84 | KDM4E (0.62) | CA1CA2MAPTNPC1RAB9A | |
| SCHEMBL5378414 | 0.83 | MAPT (0.59) | CA1CA2MAPTCES2CES1 | |
| SCHEMBL8897038 | 0.82 | PARP10 (0.53) | MAPTPARP10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4224768 | 0.82 | MAPT (0.51) | CA1CA2MAPTCES2CES1 | |
| SCHEMBL4113521 | 0.82 | HDAC3 (0.53) | CA1CA2MAPTCES2CES1 | |
| SCHEMBL9300725 | 0.82 | TDP1 (0.57) | MAPTCES2CES1NPC1RAB9A | |
| Butane SCHEMBL7720074 | 0.82 | TDP1 (0.41) | CA1CA2MAPTPLK1 | |
| SCHEMBL562943 | 0.82 | CA1 (0.63) | CA1CA2MAPTCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1884364-A | Composition for manufacturing photochromic resin lens | SHANGHAI WEIXING OPTICAL CO LT (CN) | 2006-12-27 | — | — | CN | claimed |
| WO-2025226510-A1 | LPAR1 INHIBITORS | ABBVIE INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4640274-A1 | LPAR1 INHIBITORS | AbbVie Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240287129-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2024-05-14 | — | — | US | disclosed |
| CN-114835738-B | Method for preparing allyl borate by using biomass-based catalytic material | 湖北工程学院 | 2023-09-29 | — | — | CN | disclosed |
| CN-113509961-B | Application of chitosan/cellulose composite microsphere immobilized copper in preparation of allylsilane compound | 湖北工程学院 | 2023-05-23 | — | — | CN | disclosed |
| CN-110903189-B | Synthesis method of chiral 2-aryl propionate | 大连大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| CN-1079811-C | Polymeric composite material | ASAHI CHEMICAL IND (JP) | 2002-02-27 | — | — | CN | disclosed |
| CN-1164250-A | Polymeric composite material | ASAHI CHEMICAL IND (JP) | 1997-11-05 | — | — | CN | disclosed |
| US-5670531-A | ENKEPHALINASE OR ANGIOTENSIN CONVERTING ENZYME INHIBITORS | SOCIETE CIVILE BIOPROJET (FR) | 1997-09-23 | — | — | US | disclosed |
| EP-0484122-B1 | Method for obtaining high-purity cinnamic acid | MITSUI TOATSU CHEMICALS (JP) | 1996-01-17 | — | — | EP | disclosed |
| US-5206430-A | METHOD FOR OBTAINING HIGH-PURITY CINNAMIC ACID | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-04-27 | — | — | US | disclosed |
| EP-0484122-A2 | Method for obtaining high-purity cinnamic acid | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5063225-A | Antiarrhythmia | ROUSSEL UCLAF (FR) | 1991-11-05 | — | — | US | disclosed |
| EP-0240138-B1 | PREPARATION OF CINNAMIC ACIDS | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4806683-A | Preparation process of cinnamic acids | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1989-02-21 | — | — | US | disclosed |
| EP-0240138-A1 | Preparation of cinnamic acids | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002342-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | CA1 598/4885CA2 2519/4885MAPT 3051/4885 |
| US-20240287129-A1 | DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOF | PTMS, DNPEP, QPCT | CA1 598/4885CA2 2519/4885MAPT 3051/4885 |
| US-11981704-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | CA1 598/4885CA2 2519/4885MAPT 3051/4885 |
| US-11136349-B2 | Decarboxylative conjugate additions and applications thereof | PTMS, DNPEP, QPCT | CA1 598/4885CA2 2519/4885MAPT 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.